Skip to main navigation Skip to search Skip to main content

Clinical, immunological, molecular characteristics and outcomes of stem cell transplantation in ZAP70 deficiency: a single-center experience

  • Fai AlQahtani
  • , Azhar Al Shaqaq
  • , Bandar Al-Saud
  • , Nora AlRumayyan
  • , Reem Mohammed
  • , Rand Arnaout
  • , Sahar Elshorbagi
  • , Sultan Albuhairi
  • , Ali Al-Ahmari
  • , Mouhab Ayas
  • , Hawazen Al-Saedi
  • , Abbas Hawwari
  • , Anas M. Alazami
  • , Hamoud Al-Mousa*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Zeta-chain-associated protein kinase 70 (ZAP70) deficiency is a rare autosomal recessive T+B+NK+ combined immunodeficiency characterized by heterogeneous clinical and immunologic phenotypes. Because of the limited number of reported cases, data guiding optimal management and hematopoietic stem cell transplantation (HSCT) strategies remain scarce. Methods: We retrospectively reviewed all patients with genetically confirmed ZAP70 deficiency treated at King Faisal Specialist Hospital and Research Centre. Data on pre-HSCT clinical and immunologic features, transplant characteristics, post-HSCT complications, immune reconstitution, and long-term outcomes were recorded. Results: Thirteen patients with a median age at symptom onset of 1 month were identified. The most frequent initial presentations were recurrent respiratory infections and cutaneous manifestations. Autoimmune complications and lymphoproliferation were observed in several patients. Eleven of thirteen patients (84.6%) exhibited profound CD8+ T-cell lymphopenias and two had near-normal CD8+ T-cell counts with impaired T-cell function. Eleven patients underwent HSCT, including seven from Human Leukocyte Antigen (HLA)-matched family donors, two from one-antigen mismatched related donors, one from a haploidentical mother (matched for graft-versus-host disease risk but mismatched for rejection), and one from an unrelated cord blood donor. Two patients required a second transplant because of poor immune reconstitution. Of the 11 patients who underwent HSCT, 8 (73%) remain alive with a median follow-up of 7 years (range, 1–15), and most demonstrated resolution of clinical manifestations. Conclusion: HSCT remains the only curative treatment for ZAP70 deficiency. Myeloablative conditioning regimens appear to promote more robust and durable immune reconstitution. In critically ill patients with severe infections or end-organ damage, reduced-intensity or unconditioned HSCT can be considered as a life-saving approach, although subsequent interventions might be necessary.

Original languageEnglish
Article number1656240
JournalFrontiers in Immunology
Volume16
DOIs
StatePublished - 2025
Externally publishedYes

Keywords

  • CD8 deficiency
  • hematopoietic stem cell transplant
  • immunodeficiency
  • inborn error of immunity
  • SCID
  • severe combined immunodeficiency disease
  • ZAP-70 deficiency

Fingerprint

Dive into the research topics of 'Clinical, immunological, molecular characteristics and outcomes of stem cell transplantation in ZAP70 deficiency: a single-center experience'. Together they form a unique fingerprint.

Cite this